Researchers at Penn Medicine have discovered that a patient’s awareness of a diagnosis of cognitive impairment may diminish their self-assessment of quality of life.
Rita Cowell, Ph.D., has joined the Southern Research as Chair of the Neuroscience Department as it expands research and drug discovery efforts focusing on diseases such as Parkinson’s and Alzheimer’s.
Loyola Medicine is participating in a landmark $100 million study of the effectiveness of using PET scans to detect Alzheimer's disease.
Older adults who consume alcohol moderately on a regular basis are more likely to live to the age of 85 without dementia or other cognitive impairments than non-drinkers, according to a University of California San Diego School of Medicine-led study.
Press can register here to livestream this special session through Newswise Live on Monday, July 31 at 7:30 PM EDT
Diagnosing Alzheimer’s disease and determining a patient’s prognosis is an inexact business, and that stands in the way of better personalized care and advances in treatment. A new study from The Ohio State University has identified a potential new way of confirming the disease and predicting a patient’s outlook.
The push to develop treatments for Alzheimer’s disease has yielded a greater understanding of the disease, but has failed to generate successful new drugs. To blame are the many undefined subtypes of mild cognitive impairment, a precursor to Alzheimer’s disease. But if scientists grouped people with similar types of cognitive impairment, they could more precisely test the impact of investigational drugs, according to findings in a July 28 article in the journal Scientific Reports, a publication of Nature Research.
A new method may help determine whether a person has Alzheimer’s disease or frontotemporal dementia, two different types of dementia that often have similar symptoms, according to a preliminary study published in the July 26, 2017, online issue of Neurology®, the medical journal of the American Academy of Neurology.
In a new study published today, Arizona State University-Banner Health neuroscientist Salvatore Oddo and his colleagues from Phoenix’s Translational Genomics Research Institute (TGen) — as well as the University of California, Irvine, and Mount Sinai in New York — have identified a new way for brain cells to become fated to die during Alzheimer’s diseases.
People who carry a genetic susceptibility to Alzheimer’s disease appear to be at greater risk of diminished cognition from sleep-disordered breathing than those without the susceptibility, according to new research published online, ahead of print in the Annals of the American Thoracic Society.
A report by the first Lancet Commission on Dementia Prevention and Care identifies powerful tools to prevent dementia and touts the benefits of nonmedical interventions for people with dementia.
A new study led by researchers at Washington University School of Medicine in St. Louis suggests that measures of amyloid beta in the blood have the potential to help identify people with altered levels of amyloid in their brains or cerebrospinal fluid. Currently, the only way to detect amyloid beta in the brain is via PET scanning or a spinal tap.
Emergency and urgent hospitalizations are associated with an increased rate of cognitive decline in older adults, report researchers at Rush University Medical Center. The results of their study suggest that hospitalization may be a more of a major risk factor for long-term cognitive decline in older adults than previously recognized.
Three new gene variants, found in a genome wide association study of Alzheimer’s disease (AD), point to the brain’s immune cells in the onset of the disorder. These genes encode three proteins that are found in microglia, cells that are part of the brain’s injury response system.
Researchers have found cell receptors abnormally overexpressed in post-mortem brains of those with Parkinson’s and Alzheimer’s diseases, and that they can be inhibited in animal models to clear toxic protein buildup, reduce brain inflammation, and improve cognitive performance.
Depending on what generation you belong to, the term “improvisational dance” may conjure up images of beatniks grooving to the beat of bongos in a darkened coffeehouse or the black-clad Dieter gyrating to techno pop in a Sprockets sketch on “Saturday Night Live”.
Anyone can learn whether they carry mutations known to cause Alzheimer’s, frontotemporal dementia, and other fatal neurodegenerative diseases.
Research from Washington University School of Medicine in St. Louis, Radboud University Medical Centre in the Netherlands, and Stanford University shows that disrupting just one night of sleep in healthy, middle-aged adults causes an increase in a brain protein associated with Alzheimer’s disease. Further, a week of poor sleep leads to an increase in another brain protein that has been linked to brain damage in Alzheimer’s and other neurological diseases.
Poor sleep may be a sign that people who are otherwise healthy may be more at risk of developing Alzheimer’s disease later in life than people who do not have sleep problems, according to a study published in the July 5, 2017, online issue of Neurology®, the medical journal of the American Academy of Neurology. Researchers have found a link between sleep disturbances and biological markers for Alzheimer’s disease found in the spinal fluid.
New research by scientists at the MRC Laboratory of Molecular Biology in the United Kingdom and Indiana University School of Medicine gives the most detailed view yet of tau protein structures found in Alzheimer’s disease.
Saint Louis University researchers have received a $443,636 grant from the National Institute on Aging to investigate the relationship between the diabetes drug Metformin and dementia risk.
While often used interchangeably, dementia and Alzheimer’s disease are not the same.
The connection between slowed walking speed and declining mental acuity appears to arise in the right hippocampus, a finger-shaped region buried deep in the brain at ear-level, according to a 14-year study conducted by scientists at the University of Pittsburgh Graduate School of Public Health.
Faculty, staff and graduate students are taking on one of society’s most vexing health challenges: how to prevent or slow the onset of dementia through changes in diet and exercise. And what sets the Lifestyle Interventions Group apart is its inclusion of disciplines beyond the typical confines of brain science.
Patients can engage with the Ambient Activity Technology device any time to view family photos, hear their favorite music, and play games.
Mount Sinai researchers find this network central to Alzheimer’s disease susceptibility
In a recent feasibility study, BIDMC tested an anti-epileptic drug for its potential impact on the brain activity of patients with mild Alzheimer’s disease. The team documented changes in patients’ EEGs that suggest the drug could have a beneficial effect.
Going for a walk outside, reading, listening to music—these and other enjoyable activities can reduce blood pressure for elderly caregivers of spouses with Alzheimer’s disease, suggests a study in Psychosomatic Medicine: Journal of Biobehavioral Medicine, the official journal of the American Psychosomatic Society. The journal is published by Wolters Kluwer.
Study shows seniors with dementia are on the rise. Dr. Yves Joanette is available to speak about the disease.
Is it possible to prevent dementia from happening in the first place? That’s what a leading FAU neuroscientist plans to prove using an innovative approach that defies the idea that “one-size-fits-all” when it comes to battling Alzheimer’s disease, Lewy Body Dementia, Parkinson’s disease and other related disorders. Using a personalized approach and precision medicine to reduce risk, this center is one of only a handful of centers in the world that focuses on dementia prevention.
The Mediterranean diet, rich in plant-based foods, is associated with a variety of health benefits, including a lower incidence of dementia.
The discovery hints that microglia, rather than neurons, may control much of a person’s genetic susceptibility to Alzheimer’s disease.
Professor Matthew Disney of the Department of Chemistry on the Florida campus of The Scripps Research Institute (TSRI), together with scientists from Mayo Clinic’s Florida campus and Johns Hopkins School of Medicine, has been awarded $7.2 million from the National Institute of Neurological Disorders and Stroke of The National Institutes of Health to create new RNA-based treatments for the most common form of amyotrophic lateral sclerosis (ALS), as well as a type of frontotemporal dementia (FTD).
A new study shows that people with a protective Aβ mutation have less of the peptide in their blood all through their lives, likely explaining why they do not get Alzheimer's. It suggests ways to prevent the disease in the vast majority of people who don’t have the mutation.
Hand over hand. That's how new, near-atomic resolution, 3-D snapshots show that a key biological machine unfolds a ribbon of protein through its central channel.
A new, high-resolution view of the structure of Hsp104 (heat shock protein 104), a natural yeast protein nanomachine with six subunits, may show news ways to dismantle harmful protein clumps in disease.
Duke University researchers have identified a potential new mechanism for Parkinson's disease in both mice and human endocrine cells that populate the small intestines.
The rate of death from Alzheimer’s disease in the United States increased by more than 50 percent in the past 15 years. In part, it’s because Americans are living longer – age is one of the biggest risk factors for developing Alzheimer’s. But it’s also because medical professionals can identify risk factors.
At a glance: Most frequent genetic cause of ALS and a form of dementia (FTD) is known to produce toxic peptides that interfere with RNA splicing—an intermediary step in generating functional proteins from genes. New Harvard Medical School study finds these toxic peptides block assembly of the cellular machinery responsible for RNA splicing. This blockage leads to splicing errors for genes that regulate the workings of mitochondria and neurons and the expression of other genes. Restoring normal splicing function may be a therapeutic strategy for averting or treating the development of ALS, FTD or both.
Profs. Michal Schwartz and Ido Amit at the Weizmann Institute of Science have discovered a unique immune cell type whose regulated activation may form the foundation of a future treatment for Alzheimer’s disease
According to research reported online today in Neurology, the international Dementia with Lewy Bodies Consortium issued new guidelines about diagnosing and treating the disease and called for more clinical trials into the illness.
The milestone Imaging Dementia – Evidence for Amyloid Scanning (IDEAS) Study is working with government and academic researchers to launch three add-on studies to expand the impact of the core study where more than 18,000 people with cognitive decline but an unclear diagnosis will receive an amyloid PET scan.
/PRNewswire-USNewswire/ -- The Alzheimer's Drug Discovery Foundation (ADDF), the only public charity solely focused on funding the development of drugs for Alzheimer's, and Science Exchange today announced the launch of ADDF ACCESS, a first-of-its-kind online platform designed to match scientists working on central nervous system (CNS) diseases with a vetted network of contract research organizations (CROs).
Memory loss, language problems and other symptoms of cognitive decline are strongly associated with diseases of the small blood vessels in the brain, according to a study published in the International Journal of Geriatric Psychiatry.
A founder of U.S. Alzheimer’s research, Robert D. Terry, has died at 93. He first showed what plaques and tangles look like in the electron microscope, and linked failing cognition to withering synapses in the brain.
At a meeting in Leuven, Belgium, a coherent picture began to emerge for how fluid pockets of proteins and RNAs contribute to health and disease.
Mayo Clinic Monthly News Tips — May 2017
Cognitive tests can detect early Alzheimer’s disease in older adults without symptoms according to a new Keck School of Medicine of USC study.
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right